CervoMed Inc. (CRVO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CervoMed Inc. (CRVO) has a cash flow conversion efficiency ratio of -0.249x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.47 Million) by net assets ($26.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CervoMed Inc. - Cash Flow Conversion Efficiency Trend (1998–2024)
This chart illustrates how CervoMed Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CervoMed Inc. balance sheet liabilities for a breakdown of total debt and financial obligations.
CervoMed Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CervoMed Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FACB Industries Incorporated
KLSE:2984
|
-0.007x |
|
Kartoon Studios, Inc.
NYSE MKT:TOON
|
-0.231x |
|
Galaxia SM Inc
KO:011420
|
0.005x |
|
Level Biotechnology
TWO:3118
|
0.021x |
|
DJ Mediaprint & Logistics Limited
NSE:DJML
|
-0.318x |
|
Podium Minerals Ltd
AU:POD
|
-0.007x |
|
Bafna Pharmaceuticals Limited
NSE:BAFNAPH
|
0.028x |
|
MERUS POWER OYJ EO 1
F:99H
|
N/A |
Annual Cash Flow Conversion Efficiency for CervoMed Inc. (1998–2024)
The table below shows the annual cash flow conversion efficiency of CervoMed Inc. from 1998 to 2024. For the full company profile with market capitalisation and key ratios, see CervoMed Inc. (CRVO) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $39.20 Million | $-16.53 Million | -0.422x | +58.25% |
| 2023-12-31 | $7.38 Million | $-7.45 Million | -1.010x | -453.20% |
| 2022-12-31 | $-9.00 Million | $-2.57 Million | 0.286x | +168.83% |
| 2021-12-31 | $34.91 Million | $-14.50 Million | -0.415x | +23.94% |
| 2020-12-31 | $24.81 Million | $-13.55 Million | -0.546x | -11.55% |
| 2019-12-31 | $20.13 Million | $-9.86 Million | -0.490x | +29.04% |
| 2018-12-31 | $15.61 Million | $-10.77 Million | -0.690x | -18.79% |
| 2017-12-31 | $21.23 Million | $-12.33 Million | -0.581x | +50.45% |
| 2016-12-31 | $9.18 Million | $-10.77 Million | -1.172x | -100.94% |
| 2015-12-31 | $-41.62K | $-5.19 Million | 124.578x | +52752.75% |
| 2014-12-31 | $38.17 Million | $-9.03 Million | -0.237x | -29.13% |
| 2013-12-31 | $6.47 Million | $-1.18 Million | -0.183x | -178.24% |
| 2012-12-31 | $-18.41 Million | $-4.31 Million | 0.234x | -68.84% |
| 2011-12-31 | $-16.00 Million | $-12.02 Million | 0.751x | +100.77% |
| 2010-12-31 | $20.22K | $-1.98 Million | -97.964x | -4474.39% |
| 2009-12-31 | $493.60K | $-1.06 Million | -2.142x | -85.81% |
| 2008-12-31 | $438.99K | $-505.95K | -1.153x | +61.74% |
| 1999-12-31 | $2.77 Million | $-8.35 Million | -3.012x | -133.32% |
| 1998-12-31 | $5.50 Million | $-7.10 Million | -1.291x | -- |
About CervoMed Inc.
CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of th… Read more